Obesity Management

Positive topline data from Hengrui’s phase 2 clinical trial of once-daily oral ribupatide highlight weight loss of up to 12.1% with no observed plateau at 26 weeks.

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

These data from the ongoing VESPER-3 phase 2b study highlight PF’3944’s capacity for reducing weight across 4 weekly-monthly dosing arms.

Obesity is common in CKD and drives hyperfiltration, nephron stress, and progressive kidney injury, according to experts, Kramer and Perkovic, and trial data.

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

Since 1990, the prevalence of individuals with a BMI ≥30 has increased dramatically, and without significant intervention, will continue to do so.

The investigational dual GLP-1/GIP receptor agonist resulted in substantial weight loss without plateau after 48 weeks in patients with obesity.

Weintraub discusses how patients with overweight or obesity, regardless of T2D, will regain weight in varying degrees after discontinuing therapy.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and clearances, in this week’s essential news roundup.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Susan Weiner, MS, to discuss the recently released US Dietary Guidelines.

An FDA review found no increased risk of SI/B associated with the use of GLP-1 RA medications, including liraglutide, semaglutide, and tirzepatide.

These recommendations simultaneously emphasize the efficacy of weight loss drugs and encourage incorporating lifestyle therapy on top of medication.

A new national database study suggests malnutrition reverses the obesity survival benefit in hospitalized ESKD patients undergoing dialysis

A trio of professional societies voice concerns about certain elements of the Dietary Guidelines for Americans, 2025–2030, and their potential negative health impacts.

The Q4 recap for endocrinology spotlights major FDA decisions, updates to diabetes care standards, and key clinical trial updates.

Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the groundbreaking news of oral semaglutide's approval and its cardioprotective benefits.

The approval is based on the 64-week phase 3 OASIS 4 trial showing an average weight loss of ~17% if all patients stayed on treatment with semaglutide and ~14% regardless of if patients stayed on treatment.

Singhal discusses the multi-pronged impact of the Commission’s definition of obesity and how it effects clinicians, patients, and the treatment structure itself.

Results from the ATTAIN-MAINTAIN phase 3 study have displayed orforglipron’s efficacy in maintaining weight loss without major safety concerns.

Experts redefine obesity, distinguishing between preclinical and clinical forms, aiming to improve diagnosis and treatment strategies for better health outcomes.

GLP-1 medications are revolutionizing treatment for neurological conditions.

Findings from the CARE feasibility RCT show the safety, feasibility, and likely cost-effectiveness of intentional weight loss before colorectal cancer surgery.